Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Receivables - Net: 2021-2025

Historic Receivables - Net for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $51.7 million.

  • Kiniksa Pharmaceuticals International's Receivables - Net rose 107.90% to $51.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year increase of 107.90%. This contributed to the annual value of $41.7 million for FY2024, which is 96.20% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Receivables - Net stood at $51.7 million, which was up 62.15% from $31.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Receivables - Net high stood at $51.7 million for Q3 2025, and its period low was $2.6 million during Q2 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Receivables - Net value was $24.6 million (recorded in 2023), while the average stood at $25.7 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Receivables - Net slumped by 74.78% in 2023 and then skyrocketed by 718.41% in 2024.
  • Kiniksa Pharmaceuticals International's Receivables - Net (Quarterly) stood at $4.0 million in 2021, then skyrocketed by 217.69% to $12.7 million in 2022, then soared by 67.98% to $21.3 million in 2023, then skyrocketed by 96.20% to $41.7 million in 2024, then soared by 107.90% to $51.7 million in 2025.
  • Its Receivables - Net stands at $51.7 million for Q3 2025, versus $31.9 million for Q2 2025 and $40.1 million for Q1 2025.